Aradigm first quarter total revenue decreases to $0.

The Company’s net loss for the first one fourth of 2011 was $2.4 million, or $0.01 per share, compared with a net loss of $0.2 million, or $0.00 per share, for the same period in 2010 2010. Related StoriesAmgen, Novartis collaborate for Alzheimer's disease and migraine programsMigraines might increase risk of stroke among smokersCharleston Laboratories starts Phase 1 study on CL-H1T migraine medication candidateAs of March 31, 2011, cash, money equivalents and short-term investments totaled $3.1 million.Fortunately, available chemotherapies could cure, or at least control, the condition for many sufferers. The exact factors behind DLBCLs possess remained a mystery. However, part of this mystery may have been solved with the discovery of genetic abnormalities in PRDM1. Cancer researchers have lengthy known that one genes function to suppress the out-of-control proliferation of brand-new cells – – these genes are called ‘tumor-suppressors.’ Lymphoma experts have been searching for a while for this kind of gene regarding DLBCLs, explains research senior writer Dr. Daniel M. Knowles, Professor and Chairman of the Division of Pathology and Laboratory Medication at Weill Cornell. The Weill Cornell group looked specifically at human being chromosome 6q21, a known locus for tumor suppression in large-cell lymphomas.